Eagle’s Eye View: Evidence and Innovations Targeting Inflammation Post-AMI
In this week’s View, Dr. Eagle looks at the potential value of sodium-glucose cotransporter 2 (SGLT2) agents after transcatheter aortic valve implantation (TAVI). He then explores a new randomized trial, HYPERION, focusing on the addition of sotatercept to lower the risk of clinical worsening in patients with pulmonary arterial hypertension (PAH). Finally, Dr. Eagle discusses a state-of-the-art review centered around the use of an anti-inflammatory to lessen cardiovascular events and worse outcomes following acute myocardial infarction (AMI)
X Links:
- Kim Eagle, MD, MACC keaglemd
Clinical Topics: Cardiac Surgery, Dyslipidemia, Heart Failure and Cardiomyopathies, Invasive Cardiovascular Angiography and Intervention, Pulmonary Hypertension and Venous Thromboembolism, Valvular Heart Disease, Aortic Surgery, Cardiac Surgery and Heart Failure, Cardiac Surgery and VHD, Lipid Metabolism, Acute Heart Failure, Pulmonary Hypertension, Interventions and Structural Heart Disease, Acute Coronary Syndromes
Keywords: EaglesEyeView, Pulmonary Arterial Hypertension, Anti-Inflammatory Agents, Myocardial Infarction, Inflammation, Colchicine, Atherosclerosis, Aortic Valve Stenosis, Heart Failure, Biomarkers, Transcatheter Aortic Valve Replacement, Glucose Transporter Type 2
